AR069078A1 - Derivados de piridina y pirazina - Google Patents

Derivados de piridina y pirazina

Info

Publication number
AR069078A1
AR069078A1 ARP080104644A ARP080104644A AR069078A1 AR 069078 A1 AR069078 A1 AR 069078A1 AR P080104644 A ARP080104644 A AR P080104644A AR P080104644 A ARP080104644 A AR P080104644A AR 069078 A1 AR069078 A1 AR 069078A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
amino
con
hydroxy
Prior art date
Application number
ARP080104644A
Other languages
English (en)
Inventor
Craig S Harris
Gary Fairley
Gilles Ouvry
Jon J Winter
Benedicte Delouvrie
Justin F Bower
Marie P Lambert
Bernard C Barlaam
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR069078A1 publication Critical patent/AR069078A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Composiciones farmacéuticas que los contienen y su uso en la elaboracion de un medicamento en el tratamiento de trastornos de proliferacion celular. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) donde W es CH o N; J es O o S; cada uno de G1, G2, G3 y G4 se selecciona entre CH y N con la condicion de que no más de dos de G1, G2, G3 y G4 representan N; el Anillo A se selecciona entre (i) fenilo sustituido con R1 y sustituido opcionalmente con hasta tres grupos R2; o (ii) un anillo heteroarilo monocíclico de 5 o 6 miembros con hasta tres heteroátomos del anillo que se seleccionan entre oxígeno, nitrogeno y azufre, donde dicho anillo está sustituido con R1 y opcionalmente está sustituido con hasta tres grupos R2; o (iii) un sistema de anillos bicíclico de 8, 9 o 10 miembros, donde dicho sistema de anillos bicíclico opcionalmente tiene hasta tres heteroátomos del anillo que se seleccionan entre oxígeno, nitrogeno y azufre y está sustituido opcionalmente por R1 y opcionalmente está sustituido con hasta tres grupos R2; R1 es un grupo con la formula: R4-X1- donde X1 es un enlace directo o se selecciona entre O, S, SO, SO2, N(R5), CO, CH(OR5), CON(R5), N(R5)CO, N(R5)CON(R5), SO2N(R5), N(R5)SO2, C(R5)2O, OC(R5)2, C(R5)2S, SC(R5)2, C(R5)2, C(R5)2N(R5) y N(R5)C(R5)2, donde cada R5 se selecciona independientemente entre hidrogeno, (C1-8)alquilo C1-8, hidroxi-alquilo C1-6, alcoxi C1-6-alquilo C1-6, ciano-alquilo C1-6, halogeno-alquilo C1-6, di-[alquil C1-6]amino-alquilo C1-6, alquilamino C1-6-alquilo C1-6 o amino-alquilo C1-6, y cuando X1 es un enlace directo o se selecciona entre CH(OR5), C(R5)2O, C(R5)2S, C(R5)2 o C(R5)2N(R5), donde R5 tiene cualquiera de los significados que se definieron anteriormente;, R4 es hidroxi-alquilo C1-6, alcoxi C1-6-alquilo C1-6, R5-S, R5-S(O), R5-SO2, R5-SO2-O, R5-S-alquilo C1-6, R5-S(O)-alquilo C1-6, R5-SO2-alquilo C1-6, N,N-di(R5)sulfamoilo, N,N-di-(R5)sulfamoil-alquilo C1-6, R5-SO2N(R5), R5-SO2N(R5)-alquilo C1-6, R5-CON(R5), R5O-CON(R5), R5-CON(R5)-alquilo C1-6, R5O-CON(R5)-alquilo C1-6, (R5)2N-SO2N(R5), (R5)2N-SO2N(R5)-alquilo C1-6, (R5)2N-CON(R5), (R5)2N-CON(R5)-alquilo C1-6, R5-CO, R5-CO-alquilo C1-6, R5O-CO-alquilo C1-6, (R5)2NCO, (R5)2NCO-alquilo C1-6, (R5)2N-COO, (R5)2NCOO-alquilo C1-6, ciano, amino, (R6)-amino, di-(R6)-amino, amino-alquilo C1-6, (R6)-amino-alquilo C1-6 o di(R6)-amino-alquilo C1-6, donde cada R6 que está presente es alquilo C1-6 sustituido opcionalmente con 1, 2 o 3 sustituyentes que se seleccionan independientemente entre halogeno, ciano, hidroxi y alcoxi C1-6; y cuando X1 se selecciona entre O, S, SO, SO2, N(R5), CO, CON(R5), N(R5)CO, N(R5)CON(R5), SO2N(R5), N(R5)SO2, OC(R5)2, SC(R5)2 y N(R5)C(R5)2, donde R5 tiene cualquiera de los significados que se definieron anteriormente, R4 es hidroxi-alquilo C1-6, alcoxi C1-6-alquilo C1-6, R5-S-alquilo C1-6, R5-S(O)-alquilo C1-6, R5-SO2-alquilo C1-6, N,N-di-(R5)sulfamoil-alquilo C1-6, R5-SO2N(R5)-alquilo C1-6, R5-CON(R5)-alquilo C1-6, R5O-CON(R5)-alquilo C1-6, (R5)2N-SO2N(R5)-alquilo C1-6, (R5)2N-CON(R5)-alquilo C1-6, R5-CO, R5-CO-alquilo C1-6, R5O-CO, R5O-CO-alquilo C1-6, (R5)2NCO, (R5)2NCO-alquilo C1-6, (R5)2NCOO-alquilo C1-6, amino-alquilo C1-6, (R6)-amino-alquilo C1-6 o di-(R6)-amino-alquilo C1-6, donde cada R6 que está presente es alquilo C1-6 sustituido opcionalmente con 1, 2 o 3 sustituyentes que se seleccionan independientemente entre halogeno, ciano, hidroxi y alcoxi C1-6; o R1 es un grupo con la formula: Q1-X2- donde X2 es un enlace directo o se selecciona entre O, S, SO, SO2, N(R7), N[C(O)R7], N[C(O)N(R7)2], N[C(O)OR7], N[SO2-N(R7)2], CO, CH(OR7), CON(R7), N(R7)CO, N(R7)CON(R7), SO2N(R7), N(R7)SO2, O-SO2, SO2O, C(R7)2O, OC(R7)2, C(R7)2S, SC(R7)2, C(R7)2, C(R7)2N(R7) y N(R7)C(R7)2, donde cada R7 se selecciona independientemente entre hidrogeno, alquilo C1-8, hidroxi-alquilo C1-6, alcoxi C1-6-alquilo C1-6, ciano-alquilo C1-6, halogenoalquilo C1-6, di-(R8)amino-alquilo C1-6, (R8)-amino-alquilo C1-6 o amino-alquilo C1-6, donde R8 es alquilo C1-6 sustituido opcionalmente con 1, 2 o 3 sustituyentes que se seleccionan independientemente entre halogeno, ciano, hidroxi y alcoxi C1-6; y Q1 es arilo, aril-alquilo C1-6, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, heterociclilo, heterociclil-alquilo C1-6, heteroarilo o heteroaril-alquilo C1-6, donde cualquier grupo arilo o cicloalquilo C3-8 en un sustituyente R1 lleva 1, 2 o 3 sustituyentes y cualquier grupo heterociclilo o heteroarilo en un sustituyente R1 opcionalmente tiene 1, 2 o 3 sustituyentes, donde dichos sustituyentes se seleccionan independientemente entre halogeno, trifluorometilo, ciano, nitro, hidroxi, amino, carboxi, carbamoilo, ureido, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, alcoxi C1-6, halogeno-alcoxi C1-6, hidroxi-alquilo C1-6, alcoxi C1-6-alquilo C1-6, alquilsulfonil C1-6-alquilo C1-6, ciano-alquilo C1-6, halogeno-alquilo C1-6, amino-alquilo C1-6, alquilamino C1-6-alquilo C1-6, di-[alquil C1-6]amino-alquilo C1-6, alqueniloxi C2-6, alquiniloxi C2-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, alquilamino C1-6, di-[alquil C1-6]amino, alcoxicarbonilo C1-6, alcanoilo C2-6, hidroxi-alcanoilo C2-6, alcoxi C1-6-alcanoilo C2-6, alcanoiloxi C2-6, N-alquilcarbamoilo C1-6, N,N-di-[alquil C1-6]carbamoilo, carbamoil-alquilo C1-6, N-alquil-carbamoil C1-6-alquilo C1-6, N,N-di-[alquil C1-6]carbamoil-alquilo C1-6, alcanoilamino C1-6, N-alquil C1-6-alcanoilamino C1-6, N-alquilureido C1-6, N'-alquilureido C1-6, N',N'-di-[alquil C1-6]ureido, N,N'-di-[alquil C1-6]ureido, N,N',N'-tri-[alquil C1-6]ureido, N-alquilsulfamoilo C1-6, N,N-di-[alquil C1-6]sulfamoilo, alcansulfonilamino C1-6, N-alquil C1-6-alcansulfonilamino C1-6, alcoxi C1-6-alcoxicarbonilo C1-6, alquilamino C1-6-alcanoilo C2-6, di-[alquil C1-6]amino-alcanoilo C2-6, alcanoilamino C1-6-alcanoilo C2-6, alcoxi C1-6-alcoxi C1-6-alcanoilo C2-6, heterociclilo, heterociclilalquilo C1-6, heteroarilo o heteroaril-alquilo C1-6 y algun grupo heterociclilo dentro de un sustituyente R1 opcionalmente tiene 1 o 2 sustituyentes oxo; donde, cualquier CH, CH2, o CH3 en cualquiera de los grupos alquilo que esté presente en la definicion de R4 que se conecta a X1 o que esté presente en la definicion de Q1 que se conecta a X2, opcionalmente tiene un grupo hidroxi o ciano y opcionalmente tiene hasta tres grupos halogenos, y se puede reemplazar opcionalmente por un átomo que se selecciona entre O, S o N o un grupo SO2 y los átomos de carbono adyacentes en una cadena alquilo opcionalmente pueden estar separados por la insercion en la cadena de un grupo CsC; cada uno de los grupos R2 puede ser igual o diferente y se selecciona entre halogeno, ciano, hidroxi, amino, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, alcoxi C1-6, alqueniloxi C2-6, alquiniloxi C2-6, halogeno-alcoxi C1-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, alquilamino C1-6, di-[alquil C1-6]amino, alcoxicarbonilo C1-6, alcanoilo C2-6, alcanoiloxi C2-6, carbamoilo, N-alquilcarbamoilo C1-6, N,N-di-{alquil C1-6}carbamoilo, alcanoilamino C1-6, N-alquil C1-6-alcanoilamino C1-6, alcoxi C1-6-alquilo C1-6, hidroxi-alquilo C1-6, amino-alquilo C1-6, alquilamino C1-6-alquilo C1-6, di-{alquil C1-6]amino-alquilo C1-6, alcoxi C1-6-alcoxi C1-6, hidroxi-alcoxi C1-6, amino-alcoxi C1-6, alquilamino C1-6-alcoxi C1-6 y di-[alquil C1-6]amino-alcoxi C1-6; n es 0, 1, 2 o 3 y, cuando n es 2 o 3, cada uno de los grupos R3 puede ser igual o diferente, y cada uno de los grupos R3 presente se selecciona entre hidrogeno, halogeno, amino, ciano, sulfamoilo, OR9, N-alquil-sulfamoilo C1-6, N,N-di-[alquil C1-6]sulfamoilo, trifluorometilo, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, alcoxi C1-6, alcoxicarbonilo C1-6, halogeno-alcoxi C1-6, carbamoilo, N-alquilcarbamoilo C1-6, N,N-di-[alquil C1-6]carbamoilo, alcanoilamino C1-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, hidroxi-alquilo C1-6, alcoxi C1-6-alquilo C1-6, alcanoilo C2-6, alcansulfonilamino C1-6, amino-alquilo C1-6, alquilamino C1-6-alquilo C1-6, di-[alquil C1-6]amino-alquilo C1-6, alcoxi C1-6-alcoxi C1-6, hidroxi-alcoxi C1-6, amino-alcoxi C1-6, alquilamino C1-6-alcoxi C1-6 y di-{alquil C1-6]amino-alcoxi C1-6, donde R9 es fluoro-alquilo C1-6, arilo, aril-alquilo C1-6, heterociclilo, heterociclil-alquilo C1-6, heteroarilo o heteroaril-alquilo C1-6, donde cualquier grupo arilo, heterociclilo o heteroarilo dentro de la definicion de R9 opcionalmente tiene 1, 2 o 3 sustituyentes que se seleccionan independientemente entre halogeno, fluoroalquilo C1-6, oxo, ciano, hidroxi, amino, carboxi, carbamoilo, alquilo C1-8, alquenilo C2-8, alquinilo C2-8 o alcoxi C1-6; o una sal del mismo aceptable para uso farmacéutico.
ARP080104644A 2007-10-25 2008-10-24 Derivados de piridina y pirazina AR069078A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301491 2007-10-25
EP07305005 2007-12-21
EP08305180 2008-05-19

Publications (1)

Publication Number Publication Date
AR069078A1 true AR069078A1 (es) 2009-12-30

Family

ID=40580139

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104644A AR069078A1 (es) 2007-10-25 2008-10-24 Derivados de piridina y pirazina

Country Status (18)

Country Link
US (1) US8017611B2 (es)
EP (1) EP2215085B1 (es)
JP (1) JP2011500778A (es)
KR (1) KR20100089090A (es)
CN (1) CN101910158A (es)
AR (1) AR069078A1 (es)
AT (1) ATE523508T1 (es)
AU (1) AU2008315746A1 (es)
CA (1) CA2703653A1 (es)
CL (1) CL2008003188A1 (es)
CO (1) CO6270364A2 (es)
EC (1) ECSP10010197A (es)
IL (1) IL205108A0 (es)
MX (1) MX2010004491A (es)
PE (1) PE20091116A1 (es)
TW (1) TW200920367A (es)
UY (1) UY31430A1 (es)
WO (1) WO2009053737A2 (es)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
JP2011511005A (ja) * 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド ２−アミノピリジン系キナーゼ阻害薬
EP2247600A4 (en) * 2008-02-06 2011-09-14 Biomarin Pharm Inc BENZOXAZOLEBOXYLIC ACID AMIDE AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP)
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
JP5702293B2 (ja) 2008-11-10 2015-04-15 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
AU2009322486A1 (en) * 2008-12-02 2010-06-10 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
SG10201607592PA (en) 2008-12-19 2016-11-29 Vertex Pharma Pyrazine derivatives useful as inhibitors of atr kinase
PT2361250E (pt) 2008-12-22 2013-11-11 Merck Patent Gmbh Novas formas polimórficas de di-hidrogenofosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-benzil}-2h-piridazin-3-ona e processos de fabrico das mesmas
DE102009033208A1 (de) 2009-07-15 2011-01-20 Merck Patent Gmbh Aminopyridinderivate
UY33027A (es) * 2009-11-13 2011-06-30 Astrazeneca Ab Pirazina sustituida con oxazolo[4,5-c]piridina
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN102947272A (zh) * 2010-05-12 2013-02-27 沃泰克斯药物股份有限公司 用作atr激酶抑制剂的2-氨基吡啶衍生物
US9062008B2 (en) 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2013526538A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な化合物
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
JP2013529643A (ja) 2010-06-23 2013-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用なピロロピラジン誘導体
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US8962623B2 (en) 2011-03-04 2015-02-24 Locus Pharmaceuticals, Inc. Aminopyrazine compounds
CN102718745A (zh) * 2011-03-30 2012-10-10 中国科学院上海药物研究所 新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
WO2012138938A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
WO2012138809A1 (en) * 2011-04-05 2012-10-11 Dawei Zhang Heterocyclic compounds as kinase inhibitors
WO2012161879A1 (en) 2011-05-23 2012-11-29 Merck Patent Gmbh Thiazole derivatives
WO2012161877A1 (en) 2011-05-23 2012-11-29 Merck Patent Gmbh Pyridine-and pyrazine derivatives
JP2014517079A (ja) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
WO2012178124A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2723745A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
CN103732588B (zh) * 2011-07-27 2016-10-12 南京奥昭生物科技有限公司 螺环分子作为蛋白激酶抑制剂
DE102011112978A1 (de) 2011-09-09 2013-03-14 Merck Patent Gmbh Benzonitrilderivate
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
BR112014007721B1 (pt) 2011-09-30 2022-11-01 Vertex Pharmaceuticals Incorporated Processos para preparar compostos úteis como inibidores de atr quinase
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
BR112014007690B1 (pt) 2011-09-30 2022-10-04 Vertex Pharmaceuticals Incorporated Usos de inibidores de atr no tratamento de câncer pancreático e câncer de pulmão de células não pequenas
AU2012315611A1 (en) 2011-09-30 2014-04-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN103087050A (zh) * 2011-10-28 2013-05-08 山东轩竹医药科技有限公司 芳基激酶抑制剂
WO2013071088A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776422A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776419B1 (en) 2011-11-09 2016-05-11 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
US8846918B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776420A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
DE102011119127A1 (de) 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
ES2617484T3 (es) * 2012-01-31 2017-06-19 Daiichi Sankyo Company, Limited Derivado de piridona
US9045493B2 (en) 2012-02-09 2015-06-02 Merck Patent Gmbh Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives
WO2013148537A1 (en) * 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use
CA2869309C (en) 2012-04-05 2021-02-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
US9096579B2 (en) 2012-04-20 2015-08-04 Boehringer Ingelheim International Gmbh Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
WO2013162061A1 (ja) * 2012-04-26 2013-10-31 第一三共株式会社 二環性ピリミジン化合物
ME03300B (me) 2012-06-13 2019-07-20 Incyte Holdings Corp Supsтituisana triciklična jedinjenja као inhibiтori fgfr
KR101245559B1 (ko) * 2012-06-29 2013-03-22 한국화학연구원 신규 다중치환 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 이상세포 성장 질환의 예방 및 치료용 약학적 조성물
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
EP2904406B1 (en) 2012-10-04 2018-03-21 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
WO2014062604A1 (en) 2012-10-16 2014-04-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
ES2884030T3 (es) 2012-12-07 2021-12-10 Vertex Pharma 2-amino-N-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-carboxamida como inhibidor de ATR quinasa
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
BR112015016395A2 (pt) * 2013-01-18 2017-07-11 Hoffmann La Roche pirazóis 3-substituídos e uso como inibidores de dlk
KR102202516B1 (ko) 2013-01-23 2021-01-12 아스트라제네카 아베 화합물
CA2899968C (en) * 2013-02-02 2016-12-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted 2-aminopyridine protein kinase inhibitor
EP2970311A4 (en) 2013-03-14 2016-11-23 Brigham & Womens Hospital BMP INHIBITORS AND METHODS OF USE
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
ME03015B (me) 2013-04-19 2018-10-20 Incyte Holdings Corp Biciklični heterocikli kao fgfr inhibitori
US9771333B2 (en) 2013-11-20 2017-09-26 Signalchem Lifesciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
US10233176B2 (en) 2013-11-27 2019-03-19 Signalchem Lifesciences Corporation Aminopyridine derivatives as TAM family kinase inhibitors
JP6543252B2 (ja) 2013-12-06 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ＡＴＲキナーゼ阻害剤として有用な２−アミノ−６−フルオロ−Ｎ−［５−フルオロ−ピリジン−３−イル］ピラゾロ［１，５−ａ］ピリミジン−３−カルボキサミド化合物、その調製、その異なる固体形態および放射性標識された誘導体
WO2015148654A1 (en) * 2014-03-26 2015-10-01 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
ES2761569T3 (es) 2014-04-24 2020-05-20 Novartis Ag Derivados aminopiridínicos como inhibidores de fosfatidilinositol 3-cinasas
EA033571B1 (ru) * 2014-04-24 2019-11-06 Novartis Ag Производные пиразина в качестве ингибиторов фосфатидилинозитол 3-киназы
CN106458979B (zh) 2014-04-24 2020-03-27 诺华股份有限公司 作为磷脂酰肌醇3-激酶抑制剂的氨基吡嗪衍生物
RS60013B1 (sr) 2014-06-05 2020-04-30 Vertex Pharma Radioaktivno obeleženi derivati jedinjenja 2-amino-6-fluoro-n-[5-fluoropiridin-3-il]pirazolo[1,5-a]pirimidin-3-karboksamida, korisnog kao inhibitora atr kinaze, dobijanje pomenutog jedinjenja i njegovi različiti čvrsti oblici
SG10201811175WA (en) 2014-06-17 2019-01-30 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
TWI723572B (zh) 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
US10513521B2 (en) 2014-07-15 2019-12-24 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting BMP
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3227302B1 (de) * 2014-12-02 2018-07-11 Bayer CropScience AG Bicyclische verbindungen als schädlingsbekämpfungsmittel
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
MA51229A (fr) 2015-02-20 2021-03-24 Incyte Corp Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
WO2016183071A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
PL3315131T3 (pl) 2015-06-25 2022-12-12 Taiho Pharmaceutical Co., Ltd. Środek terapeutyczny w zwłóknieniu
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
EP3355926A4 (en) 2015-09-30 2019-08-21 Vertex Pharmaceuticals Inc. METHOD FOR THE TREATMENT OF CANCER WITH A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
MX2018006207A (es) * 2015-11-19 2018-09-05 Incyte Corp Compuestos heterociclicos como inmunomoduladores.
CN116514715A (zh) 2015-12-22 2023-08-01 因赛特公司 作为免疫调节剂的杂环化合物
WO2017146236A1 (ja) 2016-02-26 2017-08-31 小野薬品工業株式会社 Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
RS65129B1 (sr) 2016-03-28 2024-02-29 Incyte Corp Jedinjenja pirolotriazina kao inhibitori tam
US20170320875A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
AU2017281285C1 (en) 2016-06-20 2022-05-12 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2018111049A1 (ko) * 2016-12-15 2018-06-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
KR102279347B1 (ko) * 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
MY197635A (en) 2016-12-22 2023-06-29 Incyte Corp Benzooxazole derivatives as immunomodulators
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
CA3053739C (en) 2017-02-15 2023-02-14 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3673907A4 (en) 2017-08-23 2020-08-19 ONO Pharmaceutical Co., Ltd. CANCER TREATMENT PHARMACEUTICAL INCLUDING AX1 INHIBITOR AS AN EFFECTIVE INGREDIENT
WO2019067594A1 (en) 2017-09-27 2019-04-04 Incyte Corporation SALTS OF PYRROLOTRIAZINE DERIVATIVES USEFUL AS TAM INHIBITORS
JP7223998B2 (ja) 2017-10-13 2023-02-17 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
IL312465A (en) 2018-05-04 2024-06-01 Incyte Corp FGFR inhibitor solid forms and processes for their preparation
PE20211918A1 (es) 2018-05-11 2021-09-28 Incyte Corp Derivados de tetrahidro-imidazo[4,5-c]piridin como inmunomoduladores de pd-l1
WO2020006408A1 (en) 2018-06-29 2020-01-02 Incyte Corporation Formulations of an axl/mer inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
KR102200032B1 (ko) * 2019-03-13 2021-01-08 전남대학교산학협력단 호흡기 질환의 예방 또는 치료용 조성물
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TW202115059A (zh) 2019-08-09 2021-04-16 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽
US11401279B2 (en) 2019-09-30 2022-08-02 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CR20220237A (es) 2019-11-11 2022-08-05 Incyte Corp Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
KR20230117573A (ko) 2020-11-06 2023-08-08 인사이트 코포레이션 Pd-1 및 pd-l1 억제제, 및 이의 염 및 결정형의 제조 방법
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG159380A1 (en) 2002-02-06 2010-03-30 Vertex Pharma Heteroaryl compounds useful as inhibitors of gsk-3
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
AU2003234464B2 (en) * 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
SE0202429D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
JP2006516626A (ja) 2003-01-28 2006-07-06 スミスクライン ビーチャム コーポレーション 化学的化合物
US7459454B2 (en) 2003-03-21 2008-12-02 Smithkline Beecham Corporation Aminopyrazine derivatives and compositions
RS51601B (en) 2004-08-26 2011-08-31 Pfizer Inc. PYRAZOLS SUBSTITUTED BY AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS
WO2006063167A1 (en) 2004-12-08 2006-06-15 Smithkline Beecham Corporation 1h-pyrrolo[2,3-b]pyridines
EP2004625B1 (en) 2006-03-22 2009-12-30 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders
EP2044051B1 (en) 2006-06-22 2010-01-27 BIOVITRUM AB (publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
EP1900727A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
GB0619342D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
KR100979439B1 (ko) 2008-04-10 2010-09-02 한국화학연구원 신규 피라졸 및 벤즈옥사졸 치환된 피리딘 유도체 또는이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물

Also Published As

Publication number Publication date
WO2009053737A2 (en) 2009-04-30
AU2008315746A1 (en) 2009-04-30
IL205108A0 (en) 2010-11-30
CO6270364A2 (es) 2011-04-20
JP2011500778A (ja) 2011-01-06
ECSP10010197A (es) 2010-06-29
ATE523508T1 (de) 2011-09-15
CN101910158A (zh) 2010-12-08
CL2008003188A1 (es) 2009-11-27
EP2215085B1 (en) 2011-09-07
UY31430A1 (es) 2009-05-29
KR20100089090A (ko) 2010-08-11
PE20091116A1 (es) 2009-08-29
WO2009053737A3 (en) 2009-07-30
EP2215085A2 (en) 2010-08-11
US20090118305A1 (en) 2009-05-07
CA2703653A1 (en) 2009-04-30
TW200920367A (en) 2009-05-16
US8017611B2 (en) 2011-09-13
MX2010004491A (es) 2010-06-21

Similar Documents

Publication Publication Date Title
AR069078A1 (es) Derivados de piridina y pirazina
AR033560A1 (es) Derivados de quinazolina, proceso para su preparacion, composicion farmaceutica, y su uso en la fabricacion de un medicamento,
AR074002A1 (es) Pirazolo e imidazopiridinilpirimidinaminas como inhibidores de la tirosina kinasa (igr-ir)
AR061651A1 (es) Analogos de piridina ii
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
AR066169A1 (es) Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
AR039222A1 (es) Derivados de quinolina e isoquinolina, un metodo para su preparacion y su uso como inhibidores de la inflamacion
AR036598A1 (es) Derivados de 4,5-dihidro-1h-pirazol que tienen potente actividad antagonista de cb1
EA200870423A1 (ru) Производные триазолпиразинов, применимые в качестве противораковых агентов
AR051215A1 (es) Derivados de quinazolina
AR045414A1 (es) Derivados de 2 - piridincarboxamida y composiciones farmaceuticas que las contienen.
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
NO20060682L (no) Indol-6 sulfonamid derivater, deres fremstilling og deres anvendelse 5-HT-6 som modulatorer
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
PE20141205A1 (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
EA201070483A1 (ru) Новые офтальмологические композиции
AR046452A1 (es) Derivados de quinazolina, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso como medicamento con efecto antiproliferativo
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
BRPI0511433A (pt) derivados de quinolina substituìda como inibidores de cinesina mitótica
CY1111747T1 (el) 8-αζαδικυκλο[3.2.1]οκτανο ενωσεις ως ανταγωνιστες μ-οπιοειδους υποδοχεα

Legal Events

Date Code Title Description
FB Suspension of granting procedure